Published in AIDS Weekly, August 8th, 2005
"To analyze the incidence, prevalence, and predictors for development of triple-class antiretroviral drug failure (TCF) in individuals infected with HIV," a population based "observational cohort study from January 1, 1995 to December 31, 2003" focused "on all 2722 recipients of highly active antiretroviral therapy (HAART) in Denmark."
"We used person-years analysis, Kaplan-Meier survival curves and Cox regression analysis. TCF was defined as a minimum of 120 days with viral load >1000 copies/ml on treatment with each of the three major drug classes," scientists writing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.